VREOF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VREOF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Vireo Growth's Capital Expenditure for the three months ended in Jun. 2024 was $-3.19 Mil. Its Revenue for the three months ended in Jun. 2024 was $25.11 Mil.
Hence, Vireo Growth's Capex-to-Revenue for the three months ended in Jun. 2024 was 0.13.
The historical data trend for Vireo Growth's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Revenue | Get a 7-Day Free Trial | 0.29 | 0.17 | 0.33 | 0.08 | 0.07 |
Vireo Growth Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Capex-to-Revenue | Get a 7-Day Free Trial | 0.11 | 0.05 | 0.10 | 0.04 | 0.13 |
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Capex-to-Revenue falls into.
Vireo Growth's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-6.054) | / | 88.133 | |
= | 0.07 |
Vireo Growth's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-3.189) | / | 25.108 | |
= | 0.13 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (OTCPK:VREOF) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of Vireo Growth's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Chicago Atlantic Credit Opportunities, Llc | 10 percent owner | 420 N WABASH AVE STE 500, CHICAGO IL 60611 |
Chicago Atlantic Manager, Llc | 10 percent owner | 420 N WABASH AVE STE 500, CHICAGO IL 60611 |
Chicago Atlantic Gp Holdings, Llc | 10 percent owner | 420 N WABASH AVE STE 500, CHICAGO IL 60611 |
Chicago Atlantic Group, Lp | 10 percent owner | 420 N WABASH AVE STE 500, CHICAGO IL 60611 |
Chicago Atlantic Group Gp, Llc | 10 percent owner | 420 N WABASH AVE STE 500, CHICAGO IL 60611 |
Chicago Atlantic Advisers, Llc | 10 percent owner | 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611 |
Joshua Rosen | director | 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Victor E. Mancebo | director | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Christian Gonzales Ocasio | officer: Chief Operating Officer | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Amber Holly Shimpa | director, officer: Chief Administrative Officer | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Patrick Peters | officer: EVP of Retail | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
J Michael Schroeder | officer: General Counsel & CCO | 3680 VICTORA STREET N, SHOREVIEW MN 55126 |
John Andrew Heller | officer: Chief Financial Officer | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Ross Michael Hussey | director | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
Judd Theodore Nordquist | director | C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402 |
From GuruFocus
By GuruFocus Research • 05-08-2024
By Marketwired • 05-01-2024
By GuruFocus Research • 02-13-2024
By Marketwired • 08-01-2024
By Marketwired • 08-03-2023
By Marketwired • 08-14-2023
By Marketwired • 07-01-2024
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 05-01-2023
By Marketwired • 07-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.